 |
市场调查报告书
商品编码
1396137
全球抗体生产市场规模、份额、成长分析（按产品类型、按流程划分）- 产业预测，2023-2030 年Global Antibody Production Market Size, Share, Growth Analysis, By Type(Monoclonal Antibody, and Polyclonal Antibody), By Process(Upstream Processing, and Downstream Processing) - Industry Forecast 2023-2030 |
||||||
2021年抗体生产市场规模为145.3亿美元，预计将从2022年的164亿美元成长到2030年的433亿美元，预测期间（2023-2030年）复合年增长率为12.9%。
抗体生产市场旨在满足用于标靶治疗、诊断和疫苗开发的抗体不断增长的需求。生物技术的进步和对分子水平疾病的更好理解正在增加对特异性和有效抗体的需求。这些抗体已成为研究疾病机制、辨识生物标记和推进个人化医疗方法的重要工具。抗体生产市场的关键驱动因素是慢性病和感染疾病的日益流行，以及对标靶治疗和诊断的需求不断增加。抗体在治疗癌症、自体免疫疾病、感染疾病等方面显示出有希望的结果。对精准医疗和个体化治疗策略的日益重视进一步推动了市场成长。儘管存在挑战，抗体生产市场仍存在一些机会。重组 DNA 技术和高通量筛检方法的发展等技术进步正在提高抗体生产的效率和扩充性。全球抗体生产市场为诊断、治疗和研究提供重要工具，在医疗保健和製药领域中发挥重要作用。市场扩张是由对标靶治疗、诊断和个人化医疗方法的追求不断增长的需求所推动的。儘管面临挑战，技术进步和不断变化的医疗保健需求正在为抗体生产市场的创新和成长创造机会。
本报告的目标细分市场
全球抗体生产市场根据类型、製程和地区进行细分。根据类型分类，市场分为单株抗体和多克隆抗体。依工艺，市场分为上游工艺和下游工艺。按地区划分，市场分为北美、欧洲、亚太地区、中东和非洲以及拉丁美洲。
促进因素
慢性病流行
慢性病的普及和标靶治疗的普及正在增加对基于抗体的治疗的需求。抗体以其特异性和功效而闻名，在多种疾病的治疗中发挥重要作用，包括癌症、自体免疫疾病和感染疾病。单株抗体 (mAb) 的出现催生了多种基于抗体治疗方法的重磅药物，并体现了治疗领域的变革方法。
生物技术的进步
生物技术和生物製药研究的不断进步加快了抗体生产过程并提高了产品品质标准。包括基因工程、细胞培养技术和高通量筛检方法的技术突破促进了新型抗体产品的创造。这些进步使抗体生产更有效率、扩充性且更具成本效益。
抑制因素
生产成本高
复杂的工艺、大量的研究和开发工作以及对抗体开发和生产的大规模生产设施的需求导致了高昂的相关成本。这些不断上涨的成本是一个主要限制因素，特别是对于中小企业来说。抗体生产的高成本阻碍了基于抗体的疗法的获取和可用性，这对市场成长构成了挑战。
严格的监管要求
抗体生产市场受到美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构制定的严格监管要求的监管。遵守这些法规对于确保抗体医药品的安全、品质和功效至关重要。然而，复杂的法律规范和严格的核准程序可能会给行业参与者带来挑战，并导致产品开发和商业化的延迟。
市场趋势：
个人化医疗日益受到关注
医疗保健行业越来越多地采用个人化医疗，这种趋势与抗体生产是一致的，允许为个别患者量身定制治疗方法。基因组和蛋白质组技术的进步正在促进特定疾病标记物的识别，为产生针对这些标记物的抗体铺平道路，并推动向个人化医疗的转变。
生物相似药的采用增加
此外，生物相似药的采用正在增加。生物相似药是一种与已确定的参考生物製药非常相似的生物製药。对具有成本效益的治疗方法的追求正在刺激生物相似药抗体的开发和接受度。随着某些着名生物製药製剂的专利到期，市场上生物相似药抗体的产量激增。这一趋势将促进竞争，拓宽市场前景，并改善基于抗体的治疗的可及性。
目录
- 执行摘要
- 调查方法
- 母市场分析
- 主要市场考察
- 技术分析
- 价格分析
- 供应链分析
- 价值链分析
- 市场生态系统
- 智慧财产权分析
- 贸易分析
- Start-Ups分析
- 原料分析
- 创新矩阵
- 研发线产品分析
- 总体经济指标
- 主要投资分析
- 关键成功因素
- 竞争程度
- 市场动态及展望
- 市场动态
- 促进因素
- 机会
- 抑制因素
- 任务
- 监管形势
- 波特的分析
- 对未来中断的特殊考察
- 市场动态
- 全球抗体生产市场：按类型
- 市场概况
- 单株抗体
- 多克隆抗体
- 全球抗体生产市场：依製程分类
- 市场概况
- 上游过程
- 下游工艺
- 全球抗体生产市场规模：按地区划分
- 市场概况
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 其他拉丁美洲地区
- 中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区
- 竞争形势
- 前5名企业对比
- 主要企业市场定位（2021年）
- 主要市场参与者所采取的策略
- 关键成功策略
- 近期市集活动
- 主要企业市场占有率（2021年）
- 主要企业简介
- Roche（Switzerland）
- Genmab（Denmark）
- Amgen（US）
- Biogen（US）
- Johnson & Johnson（US）
- AbbVie（US）
- AstraZeneca（UK）
- Novartis（Switzerland）
- Pfizer（US）
- Sanofi（France）
- Merck & Co.（US）
- Gilead Sciences（US）
- Celgene（US）
- BioMarin Pharmaceutical（US）
- Shire（Ireland）
- Alexion Pharmaceuticals（US）
- Teva Pharmaceuticals（Israel）
- Allergan（US）
- Bristol Myers Squibb（US）
- Novo Nordisk（Denmark）
Antibody production Market size was valued at USD 14.53 Billion in 2021 and is poised to grow from USD 16.40 Billion in 2022 to USD 43.30 Billion by 2030, at a CAGR of 12.9% during the forecast period (2023-2030).
The antibody production market aims to fulfill the increasing demand for antibodies utilized in the development of targeted therapies, diagnostics, and vaccines. With advancements in biotechnology and a growing understanding of diseases at the molecular level, there is a rising requirement for specific and effective antibodies. These antibodies serve as essential tools for studying disease mechanisms, identifying biomarkers, and advancing personalized medicine approaches. An essential driving factor for the antibody production market is the escalating prevalence of chronic and infectious diseases, fostering demand for targeted therapies and diagnostics. Antibodies have demonstrated promising outcomes in treating conditions like cancer, autoimmune disorders, and infectious diseases. The market's growth is further propelled by the expanding emphasis on precision medicine and personalized treatment strategies. Despite existing challenges, several opportunities exist within the antibody production market. Technological progress, including the development of recombinant DNA technology and high-throughput screening methods, has enhanced the efficiency and scalability of antibody production. The global antibody production market plays a crucial role in the healthcare and pharmaceutical sectors by providing essential tools for diagnostics, therapeutics, and research. The market's expansion is steered by the growing demand for targeted therapies, diagnostics, and the pursuit of personalized medicine approaches. While challenges persist, ongoing technological advancements and evolving healthcare needs create opportunities for innovation and growth in the antibody production market.
Segments covered in this report
The global antibody production market is segmented on the basis of type, process, and region. Based on classification by type, the market is segmented into Monoclonal Antibody, and Polyclonal Antibody. By Process, the market is segmented into Upstream Processing, Downstream Processing. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers:
prevalence of chronic diseases
The escalating prevalence of chronic diseases and the growing adoption of targeted therapies have generated a heightened demand for antibody-based therapeutics. Antibodies, known for their specificity and efficacy, play a crucial role in treating a spectrum of diseases, including cancer, autoimmune disorders, and infectious diseases. The advent of monoclonal antibodies (mAbs) exemplifies a transformative approach in the treatment landscape, yielding several blockbuster drugs rooted in antibody-based therapies.
Advancements in Biotechnology
Ongoing progress in biotechnology and biopharmaceutical research has expedited antibody production processes and elevated product quality standards. Technological breakthroughs, encompassing genetic engineering, cell culture techniques, and high-throughput screening methods, have facilitated the creation of novel antibody-based products. These advancements collectively contribute to heightened efficiency, scalability, and cost-effectiveness in antibody production.
Restraints:
High Production Costs
The intricate processes, substantial research and development endeavors, and the need for extensive manufacturing facilities in the development and production of antibodies result in high associated costs. These elevated costs can pose a significant constraint, especially for smaller and medium-sized enterprises. The expense-intensive nature of antibody production hinders the accessibility and affordability of antibody-based therapies, presenting a challenge to the growth of the market.
Stringent regulatory requirements
The antibody production market is governed by stringent regulatory requirements set forth by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adherence to these regulations is essential to guarantee the safety, quality, and efficacy of antibody-based products. Nevertheless, the intricate regulatory framework and demanding approval procedures can present challenges for industry participants, potentially causing delays in product development and commercialization.
Market Trends:
Increasing Focus on Personalized Medicine
The healthcare sector is increasingly embracing personalized medicine, a trend that aligns with antibody production by enabling tailored therapies for individual patients. Advances in genomic and proteomic technologies have facilitated the identification of specific disease markers, paving the way for the creation of antibodies targeting these markers, thus fueling the shift towards personalized medicine.
Rising Adoption of Biosimilars
Additionally, there's a growing adoption of biosimilars, which are biological products highly akin to established reference biologic drugs. The pursuit of cost-effective treatment options has spurred the development and acceptance of biosimilar antibodies. As patents expire for certain prominent biologic drugs, the market is witnessing an upsurge in biosimilar antibody production. This trend promotes competition, broadens market prospects, and enhances accessibility to antibody-based therapies.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Market Dynamics
- Global Antibody Production Market by Type
- Market Overview
- Monoclonal Antibody
- and Polyclonal Antibody
- Global Antibody Production Market by Process
- Market Overview
- Upstream Processing
- and Downstream Processing
- Global Antibody Production Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genmab (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioMarin Pharmaceutical (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shire (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alexion Pharmaceuticals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceuticals (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche (Switzerland)
研究抗体市场：按适应症、按操作、按产品、按来源、按技术、按类型、按最终用户 - 2024-2030 年，全球预测
抗体发现市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按抗体类型、性质、服务、最终用户和地理位置
全球抗体药物复合体市场：2024年至2029年预测
抗体生产市场：按产品类型、製程和最终用户划分 - 2024-2030 年全球预测
抗体药物复合体契约製造市场：按连结器、条件和最终用途划分 - 2024-2030 年全球预测
研究抗体的全球市场
多克隆抗体市场：按类型、来源、应用、最终用户、地区![抗体治疗市场- 按类型[单株抗体(mAb) {肿瘤、自体免疫疾病、传染病}、抗体药物偶联物(ADC)]、按最终用途（医院、专科中心）划分- 全球预测，2023年- 2032 年](/sample/img/cover/42/1416204.png)
抗体治疗市场- 按类型[单株抗体(mAb) {肿瘤、自体免疫疾病、传染病}、抗体药物偶联物(ADC)]、按最终用途（医院、专科中心）划分- 全球预测，2023年- 2032 年
抗体药物偶联物市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测
多株抗体抗体市场规模 - 按产品（一抗、二抗）、应用、给药途径（IV、SC）、来源（兔、山羊、小鼠、人类）、最终用户、全球预测（2023-2032）